噬菌体市场：现状分析与预测（2022-2028）

噬菌体市场预计将以 4.5% 的复合年增长率增长。 这是由于全世界患者中抗生素耐药性日益普遍。 例如，根据疾病控制与预防中心 2021 年 12 月的一份报告，美国各地每年发生超过 280 万例抗生素感染。 此外，随着细菌对抗生素的抵抗力增强，对替代治疗的需求也随之增加。 噬菌体可能提供一种解决方案，因为它们可以专门针对并杀死细菌，而不伤害人类或其他生物体。 此外，噬菌体可以针对特定的细菌菌株进行定制，使其比传统抗生素更有效。 因此，上述因素预计将推动市场增长。

根据产品类型，市场分为益生元和治疗前药物。 其中，益生元领域预计在预测期内将以较大的复合年增长率增长。 益生元可以帮助促进噬菌体生长，减少肠道中有害细菌的数量，并改善您的整体健康。 因此，益生元行业预计将受益于噬菌体市场的增长。 因此，上述因素预计将在预测期内推动市场增长。

根据应用类型，市场分为胃肠道、呼吸道感染、尿路感染等。 其中，呼吸道感染领域预计在预测期内将以较大的复合年增长率增长。 这是由于肺炎球菌引起的肺炎球菌疾病的患病率不断增加。 例如，根据美国疾病控制与预防中心 2019 年的一份报告，美国每年发生超过 3000 万例肺炎球菌感染，其中超过 30% 的感染中，该细菌与一种或多种临床症状有关。对相关抗生素有耐药性。 这一因素正在推动市场对噬菌体的需求。

根据给药途径，市场分为口服途径、局部途径和肠胃外途径。 其中，口服给药途径预计在预测期内将以显着的复合年增长率增长。 口服给药途径因其较高的患者依从性和成本效益而被优选为最方便的给药途径。 此外，口服途径给药的药物在设计和製造过程中具有更大的灵活性，并且比其他给药途径具有更少的无菌限制。 因此，上述因素正在推动市场增长。

预计亚太地区在预测期内将以显着的复合年增长率增长。 这是由于该地区医疗保健支出增加。 例如，2021财年支付给医疗机构的医疗保健支出创下历史新高，达到316万亿美元，比上年增加14万亿美元（4.6%）。 这正在推动该地区的市场增长。

目录

第一章市场介绍

• 市场定义
• 主要目的
• 利益相关者
• 限制

第二章研究方法或假设

• 调查过程
• 调查方法
• 受访者简介

第三章市场总结

第 4 章执行摘要

第五章新型冠状病毒感染（COVID-19）对全球噬菌体市场的影响

第 6 章全球噬菌体市场收入，2020-2028

第 7 章按产品类型划分的市场洞察

第 8 章按应用划分的市场洞察

• 胃肠道
• 呼吸道感染的治疗
• 尿路感染
• 其他

第 9 章最终用户的市场洞察

• 口服途径
• 本地路线
• 肠胃外途径

第 10 章按地区划分的市场洞察

• 北美市场
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲市场
  • 英国
  • 德国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲地区
• 亚太市场
  • 中国
  • 日本
  • 印度
  • 韩国
  • 亚太地区的其他国家/地区
• 世界其他地区的市场

第 11 章噬菌体市场动态

• 市场驱动因素
• 市场挑战
• 影响分析

第12章噬菌体市场机会

第13章噬菌体市场趋势

第14章需求侧和供给侧分析

• 需求方分析
• 供给侧分析

第 15 章战略洞察

第16章竞争场景

• 竞争状况
  • 波特五力分析

第17章公司简介

• Armata Pharmaceuticals, Inc.
• Life Extension.
• Arthur Andrew Medical.
• Biochimpharm
• Micreos
• biostation.
• Probiotic America, LLC.
• Eliava BioPreparations
• Locus Biosciences, Inc.
• BiomX.

第18章 免责事项

Bacteriophages also known as phage viruses are a group of viruses, that infect and replicate inside bacteria. They are the most abundant biological entities on Earth and play an important role in regulating bacterial populations in various environments. Phages have been used as a therapeutic agent for treating bacterial infections, and they also have potential applications in biotechnology and biodefense.

The bacteriophage market is anticipated to grow with a CAGR of 4.5%. This is attributed to the increase in the prevalence of developing antibiotic resistance amongst patients globally. For instance, according to the Centre for disease control and Prevention's December 2021 report, around the United States, more than 2.8 million anti-microbial infections occur each year. Additionally, as bacteria become increasingly resistant to antibiotics, there is a growing need for alternative treatments. Bacteriophages may offer a solution as they can specifically target and kill bacteria without harming humans or other organisms. Further, bacteriophages can be tailored to specific bacterial strains, which may make them more effective than traditional antibiotics. Thus, the above-mentioned elements are anticipated to boost market growth.

Based on product type, the market is bifurcated into pre-biotic and pre-therapeutics. Amongst this, the pre-biotic segment is anticipated to grow with a significant CAGR in the forecasted period. Pre-biotics can help to promote the growth of bacteriophages, which can help to reduce the number of harmful bacteria in the gut and improve overall health. Therefore, the pre-biotic segment is expected to benefit from the growth of the bacteriophage market. Thus, this above-mentioned factor is anticipated to fuel the market growth in the forecasted period.

Based on the application type, the market is segmented into the gastrointestinal tract, respiratory tract infection, urinary tract infections and others. Amongst this, the respiratory tract infection segment is anticipated to grow with a significant CAGR in the forecasting period. This is attributed to the rising incidence of pneumococcal disease, caused by the bacteria streptococcus pneumonia. For instance, according to the Centre for disease control and Prevention 2019 report, more than 30 million pneumococcal infections occur each year in the United States, amongst this in more than 30% of infections, the bacteria are resistant to one or more clinically relevant antibiotics. This element is driving the market demand for bacteriophage.

Based on the route of administration, the market is segmented into oral, topical and parenteral routes. Amongst these, the oral route of administration is anticipated to grow with a significant CAGR during the forecasting period. oral route of drug administration is preferred and is the most convenient route of drug administration due to its high patient compliance and cost-effectiveness. Additionally, the oral route drugs are flexible in design and production process and have fewer sterility constraints contrary to other routes of administration. Thus, these above-mentioned factors are fueling the growth of the market.

For a better understanding of the market adoption of the Behavior Health industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (UK, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Rest of World. Asia-pacific is anticipated to grow with a significant CAGR during the forecasted period. This is attributed to the increase in healthcare expenditure in this region. For instance, healthcare expenditures paid to medical institutions in fiscal 2021 reached a record USD 316 trillion, an increase of 14 trillion, or 4.6%, compared to the previous year. This is propelling the market growth in this region.

Some of the major players operating in the market include: Armata Pharmaceuticals, Inc., Life Extension., Arthur Andrew Medical., Biochimpharm, Micreos, biostation., Probiotic America, LLC., Eliava BioPreparations, Locus Biosciences, Inc., BiomX.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Bacteriophage Market
• 2.2. Research Methodology of the Bacteriophage Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL BACTERIOPHAGE MARKET COVID-19 IMPACT

6 GLOBAL BACTERIOPHAGE MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY PRODUCT TYPE

• 7.1. Phage Pro-biotic
• 7.2. Phage Therapeutics

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Gastrointestinal tract
• 8.2. Respiratory Infection Treatment
• 8.3. Urinary Tract Infection
• 8.4. Others

9 MARKET INSIGHTS BY END-USERS

• 9.1. Oral
• 9.2. Topical
• 9.3. Parenteral

10 MARKET INSIGHTS BY REGION

• 10.1 North America Market
  • 10.1.1 U.S.
  • 10.1.2 Canada
  • 10.1.3 Rest of North America
• 10.2 Europe Market
  • 10.2.1 UK
  • 10.2.2 Germany
  • 10.2.3 France
  • 10.2.4 Italy
  • 10.2.5 Spain
  • 10.2.6 Rest of Europe
• 10.3 Asia-Pacific Market
  • 10.3.1 China
  • 10.3.2. Japan
  • 10.3.3 India
  • 10.3.4 South Korea
  • 10.3.5 Rest of APAC
• 10.4 Rest of the World Market

11 BACTERIOPHAGE MARKET DYNAMICS

• 11.1 Market Drivers
• 11.2 Market Challenges
• 11.3 Impact Analysis

12 BACTERIOPHAGE MARKET OPPORTUNITIES

13 BACTERIOPHAGE MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1 Demand Side Analysis
• 14.2 Supply Side Analysis

15 STRATEGIC INSIGHTS

16 COMPETITIVE SCENARIO

• 16.1 Competitive Landscape
  • 16.1.1 Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1 Armata Pharmaceuticals, Inc.
• 17.2. Life Extension.
• 17.3 Arthur Andrew Medical.
• 17.4. Biochimpharm
• 17.5. Micreos
• 17.6. biostation.
• 17.7. Probiotic America, LLC.
• 17.8. Eliava BioPreparations
• 17.9. Locus Biosciences, Inc.
• 17.10. BiomX.

18 DISCLAIMER